NCT01916148

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

Expanded Access Use of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Children's Hospital of Philadelphia · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This purpose of this study is to determine the ability of an 18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET (Positron Emission Tomography) scan to detect a focal lesion of hyperinsulinism and determine the location in patients with congenital hyperinsulinism, Beckwith Wiedemann Syndrome and suspected insulinoma. Safety data will be collected.

Detailed description

Patients with hyperinsulinemic hypoglycemia are at risk for neurological damage due to hypoglycemia. Early surgical intervention can be preventative. F-DOPA PET may be able to detect of a focal lesion prior to surgical intervention and be used during surgical planning to guide the surgical procedure.

Conditions

• Congenital Hyperinsulinism (CHI)
• Beckwith-Wiedemann Syndrome
• Insulinoma

Interventions

Type	Name	Description
DRUG	18F-DOPA	18F-DOPA is a PET (Positron Emission Tomography) scan radiotracer.

Timeline

• First posted: 2013-08-05
• Last updated: 2025-04-02

Locations

1 site across 1 country: United States